Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype
- PMID: 37927462
- PMCID: PMC10622971
- DOI: 10.3389/fonc.2023.1278863
Features of the immunosuppressive tumor microenvironment in endometrial cancer based on molecular subtype
Abstract
Endometrial cancer (EC) is one of the three most prevalent gynecological tumors affecting women and is the most prevalent gynecological malignancy in the developed world. Its incidence is rapidly increasing worldwide, mostly affecting postmenopausal women, whereas recently its prevalence has increased in younger people. EC is an immune gene disease and many studies have shown that the tumor-immunosuppressive microenvironment plays an important role in cancer progression. In recent years, findings regarding the immunosuppressive tumor microenvironment (ITME) of EC have included immune evasion mechanisms and immunotherapy, which are mostly immune checkpoint inhibitors (ICI) for EC. Recently studies on the ITME of different molecular types of EC have found that different molecular types may have different ITME. With the research on the immune microenvironment of EC, a new immunophenotype classification based on the immune microenvironment has been carried out in recent years. However, the impact of the ITME on EC remains unclear, and the immunophenotype of EC remains limited to the research stage. Our review describes recent findings regarding the ITME features of different EC molecular types. The advent of immunotherapy has brought hope for improved efficacy and prognosis in patients with advanced or recurrent EC. The efficacy and safety of ICIs combination therapy remains the focus of future research.
Keywords: endometrial cancer; immunophenotype; immunosuppressive tumor microenvironment; immunotherapy; molecular subtypes.
Copyright © 2023 Zhang, Wang and Wu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy.Oncol Lett. 2020 Sep;20(3):2075-2090. doi: 10.3892/ol.2020.11774. Epub 2020 Jun 25. Oncol Lett. 2020. PMID: 32782525 Free PMC article. Review.
-
Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy.Acta Pharmacol Sin. 2022 Dec;43(12):3045-3054. doi: 10.1038/s41401-022-00976-6. Epub 2022 Sep 1. Acta Pharmacol Sin. 2022. PMID: 36050519 Free PMC article. Review.
-
Immune checkpoint inhibitors for recurrent endometrial cancer.Expert Rev Anticancer Ther. 2022 Mar;22(3):249-258. doi: 10.1080/14737140.2022.2044311. Epub 2022 Feb 24. Expert Rev Anticancer Ther. 2022. PMID: 35176955 Review.
-
Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.Cancers (Basel). 2023 Mar 29;15(7):2042. doi: 10.3390/cancers15072042. Cancers (Basel). 2023. PMID: 37046702 Free PMC article. Review.
-
Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.Int J Pharm. 2019 Oct 30;570:118636. doi: 10.1016/j.ijpharm.2019.118636. Epub 2019 Aug 22. Int J Pharm. 2019. PMID: 31446027 Review.
Cited by
-
Advances in Immunotherapy for Endometrial Cancer: Insights into MMR Status and Tumor Microenvironment.Cancers (Basel). 2024 Nov 22;16(23):3918. doi: 10.3390/cancers16233918. Cancers (Basel). 2024. PMID: 39682106 Free PMC article. Review.
-
Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape.Front Immunol. 2024 Aug 20;15:1425212. doi: 10.3389/fimmu.2024.1425212. eCollection 2024. Front Immunol. 2024. PMID: 39229264 Free PMC article. Review.
-
The Deep Proteomics Approach Identified Extracellular Vesicular Proteins Correlated to Extracellular Matrix in Type One and Two Endometrial Cancer.Int J Mol Sci. 2024 Apr 24;25(9):4650. doi: 10.3390/ijms25094650. Int J Mol Sci. 2024. PMID: 38731868 Free PMC article.
-
Precision medicine in gynecological cancer (Review).Biomed Rep. 2025 Jan 8;22(3):43. doi: 10.3892/br.2025.1921. eCollection 2025 Mar. Biomed Rep. 2025. PMID: 39810899 Free PMC article. Review.
-
The Clinical and Pathological Characteristics of POLE-Mutated Endometrial Cancer: A Comprehensive Review.Cancer Manag Res. 2024 Mar 4;16:117-125. doi: 10.2147/CMAR.S445055. eCollection 2024. Cancer Manag Res. 2024. PMID: 38463556 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources